Dimeric immunoglobulin A as a novel diagnostic marker of measles infection
Preprint
Abstract
Despite tremendous measles incidence reduction through universal vaccination, elimination efforts rely on improved surveillance. Detection of anti-measles immunoglobulin M (IgM) by ELISA is the standard laboratory diagnostic method. However, true infection is rare and seroconversion following MMR vaccination also generates IgM, which results in low positive predictive values of assays in elimination settings, thus necessitating confirmatory testing. Improved diagnostic tests for measles infection are a World Health Organization (WHO) research priority. We investigated whether dimeric immunoglobulin A (dIgA), the predominant antibody produced in mucosal immunity, may be a marker of recent or acute measles infection. We examined a serological panel of confirmed measles infection (anti-measles IgM positives, n=50), and non-measles infection with rubella (n=36), roseola (n=40), chikungunya/dengue/zika (n=41), parvovirus (n=35) and other fever-rash illness of unknown cause (n=37). Sera were examined on a Micrommune anti-measles IgM, Euroimmun anti-measles virus lysate (VL) and nucleoprotein (NP) IgM kits. Assays were then modified to detect dIgA using an in-house protocol based on a recombinant chimeric secretory component protein and anti-secretory component monoclonal antibody. We observed significantly higher levels of anti-measles VL dIgA in measles samples than non-measles controls (p2 : 0.01, p value:0.487). Unlike IgM, dIgA reactive to measles NP was not detected in most samples. Comparable diagnostic potential of anti-measles dIgA (AUC 0.920 - 0.945) to anti-measles IgM (AUC 0.986 – 0.995), suggests that dIgA may be a new blood-based marker of acute measles, independent of IgM, which merits further investigation and optimization.Keywords
All Related Versions
- Published version: Microbiology Spectrum, 12 (1), e0343723.
This publication has 22 references indexed in Scilit:
- Serological assays to measure dimeric IgA antibodies in SARS‐CoV‐2 infectionsImmunology & Cell Biology, 2023
- Measles in the 21st Century: Progress Toward Achieving and Sustaining EliminationThe Journal of Infectious Diseases, 2021
- Dimeric IgA is a specific biomarker of recent SARS-CoV-2 infectionmedRxiv, 2021
- Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort studyHuman Vaccines & Immunotherapeutics, 2021
- IgA dominates the early neutralizing antibody response to SARS-CoV-2Science Translational Medicine, 2021
- Rapid diagnostic tests to address challenges for global measles surveillanceCurrent Opinion in Virology, 2020
- Serum anti-tetanus and measles antibody titres in Ugandan children aged 4 months to 6 years: implications for vaccine programmeEpidemiology and Infection, 2018
- Mucosal IgA Responses in Healthy Adult Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles VaccineClinical and Vaccine Immunology, 2011
- Persistence of Measles Antibodies After 2 Doses of Measles Vaccine in a Postelimination EnvironmentArchives of Pediatrics & Adolescent Medicine, 2007
- Simultaneous IgM reactivity by EIA against more than one virus in measles, parvovirus B19 and rubella infectionJournal of Clinical Virology, 1999